FTC Charges False Security From ADT

March 7 (Bloomberg) –- The Federal Trade Commission is accusing alarm maker ADT of false security. The company settled a complaint that it planted paid spokesmen on TV and radio shows to endorse their products. Bloomberg's Megan Hughes has the details. (Source: Bloomberg)

Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
04:01 - Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO Stegfan Oschmann speaks on "Bloomberg Daybreak Europe." (Source: Bloomberg)
  • Aviva's Diebel Sees No Macro Impact From Healthcare Bill
  • Italy Junior Minister Sees Brexit as EU Opportunity
  • French Presidential Race Takes an Inflammatory Turn